ROR1-PI3K/AKT signaling drives adaptive resistance to cell cycle blockade in TP53 mutated ovarian cancer
Juuli Raivola(University of Helsinki), Daniela Ungureanu(Institute for Molecular Medicine Finland)
Cited by 1
Related Papers
Evaluating Targeted Therapies in Ovarian Cancer Metabolism: Novel Role for PCSK9 and Second Generation mTOR Inhibitors
|Cancers|2021|31
New insights into the molecular mechanisms of ROR1, ROR2, and PTK7 signaling from the proteomics and pharmacological modulation of ROR1 interactome
|Cellular and Molecular Life Sciences|2022|13